Rodrigo Alonso, Raquel Arroyo-Olivares, Jose Luis Díaz-Díaz, Francisco Fuentes-Jiménez, Francisco Arrieta, Raimundo de Andrés, Pablo Gonzalez-Bustos, Rosa Argueso, Mercedes Martin-Ordiales, Ceferino Martinez-Faedo, Fátima Illán, Pedro Saenz, José María Donate, Juan F Sanchez Muñoz-Torrero, Sergio Martinez-Hervas, Pedro Mata
AIM: We aimed to describe clinical and genetic characteristics, lipid-lowering treatment and atherosclerotic cardiovascular disease (ASCVD) outcomes over a long-term follow-up in homozygous familial hypercholesterolemia (HoFH). METHODS: SAFEHEART (Spanish Familial Hypercholesterolaemia Cohort Study) is a long-term study in molecularly diagnosed FH. Data analyzed in HoFH were prospectively obtained from 2004 until 2022. ASCVD events, lipid profile and lipid-lowering treatment were determined...
March 16, 2024: Atherosclerosis